Sharing this page with your friends could help raise up to 3x more in donations
Diazepam tablets require a valid prescription from a DEA-registered US healthcare provider as a Schedule IV controlled substance for anxiety, muscle spasms, seizures, or alcohol withdrawal; no speed-first delivery network or online service can legally dispense them without comprehensive medical evaluation, and prescription-free "buy online" constitutes federal felony distribution under 21 U.S.C. § 841, punishable by up to 20 years imprisonment, $250,000 fines, and supervised release.
Common strengths (2mg, 5mg, 10mg) follow precise regimens (anxiety: 2-10mg BID-QID max 40mg/day; alcohol withdrawal: 10mg TID-QID Day 1 tapering; seizures: 0.2-0.5mg/kg loading) under 2025 DEA telemedicine flexibilities through 12/31/2025, mandating synchronous HIPAA video with DSM-5/CIWA-Ar confirmation, PDMP review, SUD exclusion (CAGE<2), and shortest duration/lowest dose—post-2025 requires in-person initiation or special registration with EPCS and 5-refill/6-month limits; no "network" bypasses Ryan Haight Act safeguards or state quantity caps.
GABA-A agonist (Ki 10nM allosteric), Tmax 1h oral, t½ 20-50h (active desmethyldiazepam t½ 100h); anxiety elderly start 2mg BID/5mg adults; spasticity 2-10mg TID-QID; status epilepticus 0.2mg/kg IV/rectal/nasal; contraindications: acute narrow-angle glaucoma, severe respiratory depression (RR<12), myasthenia gravis, pregnancy Category D; black box: physical dependence (tolerance 2-4wks), respiratory arrest with opioids (OR 8), withdrawal seizures (30% abrupt >20mg equivalents)—APA 2025 joint guideline mandates hyperbolic tapers (20%→10%→5% reductions).
Screening Tools: HAM-A>18 or CIWA-Ar>10 with documented impairment.
Synchronous Video: 20-40min PDMP clean across states, baseline LFTs/BP/ECG.
Risk Mitigation: Informed consent (25% dependence rate), naloxone co-Rx if MME>20.
EPCS Parameters: #30 tabs initial, limited refills, C-IV pharmacy direct.
Fulfillment: Signature-required 2-day tamper-evident tracked delivery.
Oversight Protocol: Biweekly initial assessments, monthly with taper roadmap per APA hyperbolic guidance.
| Frequency | Effects | Rate | Evidence-Based Management |
|---|---|---|---|
| >20% | Sedation, ataxia, dizziness | Dose-linear | Divided BID-QID, avoid ethanol/machinery |
| 5-15% | Amnesia, cognitive impairment, falls | Elderly x3 | MoCA serial screening, max 10mg/day geriatric |
| 1-5% | Respiratory depression, hypotension | Opioid synergy OR 8 | Naloxone 0.4mg IN standby kit |
| <1% | Paradoxical disinhibition, hepatic toxicity | Abrupt DC | Immediate reinstatement + slow taper |
Overdose Reversal: Flumazenil 0.2mg IV titrated (high seizure rebound 20-30% risk); Interactions: CYP3A4/2C19 inhibitors double AUC (e.g., fluoxetine), alcohol OR 10 respiratory depression.
Joint APA/ASAM guideline emphasizes individualized hyperbolic tapers avoiding abrupt cessation: physical dependence expected after regular use ≠ SUD; taper indications include falls/cognition/opioid co-Rx; reduction sequence 20%→10%→5% with q1-2wk monitoring—seizure risk highest Days 3-7 post-abrupt stop.
| Therapy | Efficacy (HAM-A Reduction) | Onset | Dependence Risk |
|---|---|---|---|
| Lorazepam 0.5-2mg PRN | Acute equivalent potency | 30min | Moderate-short acting |
| Buspirone 15-60mg/day | Chronic GAD 45% | 3wks | None |
| Hydroxyzine 25-50mg TID | Acute 40% | 15-30min | Minimal |
| CBT (12-16 sessions) | 60-70% sustained | 8wks | Zero |
| Gabapentin 300-1200mg TID | Adjunct 35-45% | 1wk | Tolerance 20% |
Legal diazepam speed delivery no prescription USA? No—Schedule IV felony up to 20 years.
Telemedicine availability end date? Synchronous video flexibilities expire 12/31/2025.
Alcohol withdrawal peak dose? 10mg TID-QID Day 1 with taper.
Abrupt cessation seizure probability? 30% >20mg equivalents daily.
APA hyperbolic taper definition? 20%→10%→5% reductions as doses decrease.